LabCorp Completes and Publishes a Clinical Study for the Development and Validation of a PCR Assay for the Diagnosis of Bacterial Vaginosis
During the study, quantitative PCR assays were developed for 4
organisms reported previously to be useful positive indicators for the
diagnosis of bacterial vaginosis (BV) and a single organism that had
been implicated as a negative indicator for BV. A total of 402 women
were enrolled in the study between April and
The new test, which is called Bacterial Vaginosis, is currently available as part of the NuSwabsm series of tests. In 2011, LabCorp introduced NuSwab as a single collection device that improves the convenience and efficacy of sample collection for clinically validated test profiles for targeted women’s health clinical conditions. The tests are configured to be cost-effective for payers and patients, while providing high quality results to guide diagnosis & treatment.
“Bacterial vaginosis is a common condition, but physicians have limited
tools to diagnose it properly,” said Dr.
This enhancement to LabCorp’s test menu is an adjunct to its broad women’s health test options, including tests that focus on both screening and diagnosis of disease. In addition to its women’s health services, LabCorp offers a comprehensive menu of individual tests and test combinations to address specific patient needs.
About LabCorp®
This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive actions in
the marketplace and adverse actions of governmental and other
third-party payors. Actual results could differ materially from
those suggested by these forward-looking statements. Further information
on potential factors that could affect LabCorp’s financial results is
included in the Company’s Form 10-K for the year ended
Source:
Laboratory Corporation of America® Holdings
Stephen
Anderson, 336-436-5076
www.labcorp.com